Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease In the Presence of Low or Castrate Testosterone Levels

Overview

Journal JACC Basic Transl Sci

Date 2024 Apr 1

PMID 38559622

Authors

Wilhelmina C M Duivenvoorden

David Margel

Vishal Subramony Gayathri

Emmanuelle Duceppe

Sadiya Yousef

Magda Naeim

Mohammad Khajehei

Sarah Hopmans

Snezana Popovic

Yaara Ber

Diane Heels-Ansdell

Philip J Devereaux

Jehonathan H Pinthus

Affiliations

Soon will be listed here.

Abstract

Low testosterone (T), common in aging men, associates with cardiovascular disease. We investigated whether follicle-stimulating hormone (FSH), which is affected by T, modulates the cardiovascular effects associated with low T or castration. FSHβ:low-density lipoprotein receptor (LDLR) mice, untreated or castrated (orchiectomy, gonadotropin-releasing hormone agonist or antagonist), demonstrated significantly less atherogenesis compared with similarly treated LDLR mice, but not following FSH delivery. Smaller plaque burden in LDLR mice receiving gonadotropin-releasing hormone antagonists vs agonists were nullified in FSHβ:LDLR mice. Atherosclerotic and necrotic plaque size and macrophage infiltration correlated with serum FSH/T. In patients with prostate cancer, FSH/T following androgen-deprivation therapy initiation predicted cardiovascular events. FSH facilitates cardiovascular disease when T is low or eliminated.

Citing Articles

Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis.

Alinejad Khorram A, Pourasgharian R, Shams A, Toufani S, Mostafaei M, Khademi R BMC Cardiovasc Disord. 2024; 24(1):756.

PMID: 39736562 PMC: 11684147. DOI: 10.1186/s12872-024-04421-w.

Research progress on FSH-FSHR signaling in the pathogenesis of non-reproductive diseases.

Li C, Ling Y, Kuang H Front Cell Dev Biol. 2024; 12:1506450.

PMID: 39633710 PMC: 11615068. DOI: 10.3389/fcell.2024.1506450.

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.

Reiss A, Vasalani S, Albert J, Drewes W, Li K, Srivastava A Medicina (Kaunas). 2024; 60(11).

PMID: 39596912 PMC: 11596556. DOI: 10.3390/medicina60111727.

The need for precision medicine in managing cardiovascular risk for men receiving ADT.

Hahn A, Koutroumpakis E, Narayan V, Aparicio A Prostate Cancer Prostatic Dis. 2024; .

PMID: 38796515 DOI: 10.1038/s41391-024-00848-6.

Cardiovascular risk in ADT recipients: does the type of ADT matter?.

Pinthus J, Duivenvoorden W Prostate Cancer Prostatic Dis. 2024; 27(3):435-437.

PMID: 38664503 DOI: 10.1038/s41391-024-00832-0.

References

Botto F, Srinathan S, Pearse R, Biccard B, Rodseth R, Sheth T . Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology. 2014; 120(3):564-78. DOI: 10.1097/ALN.0000000000000113. View

Hopmans S, Duivenvoorden W, Werstuck G, Klotz L, Pinthus J . GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol. 2014; 32(8):1126-34. DOI: 10.1016/j.urolonc.2014.06.018. View

Munir J, Wu H, Bauer K, Bindeman J, Byrd C, Feuerstein I . The perimenopausal atherosclerosis transition: relationships between calcified and noncalcified coronary, aortic, and carotid atherosclerosis and risk factors and hormone levels. Menopause. 2011; 19(1):10-5. DOI: 10.1097/gme.0b013e318221bc8d. View

Wu F, Tajar A, Beynon J, Pye S, Silman A, Finn J . Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010; 363(2):123-35. DOI: 10.1056/NEJMoa0911101. View

Lopes R, Higano C, Slovin S, Nelson A, Bigelow R, Sorensen P . Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation. 2021; 144(16):1295-1307. PMC: 9004319. DOI: 10.1161/CIRCULATIONAHA.121.056810. View

Ishibashi S, Brown M, Goldstein J, Gerard R, Hammer R, Herz J . Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993; 92(2):883-93. PMC: 294927. DOI: 10.1172/JCI116663. View

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating N, Van Hemelrijck M . Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2014; 68(3):386-96. DOI: 10.1016/j.eururo.2014.11.039. View

Crawford E, Tombal B, Keane T, Boccardo F, Miller K, Shore N . FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2019; 52(5-6):349-357. DOI: 10.1080/21681805.2018.1522372. View

Morgentaler A, Traish A . Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2008; 55(2):310-20. DOI: 10.1016/j.eururo.2008.09.024. View

10.

Klotz L, Boccon-Gibod L, Shore N, Andreou C, Persson B, Cantor P . The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102(11):1531-8. DOI: 10.1111/j.1464-410X.2008.08183.x. View

11.

Damas J, Smith C, Oie E, Fevang B, Halvorsen B, Waehre T . Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006; 27(3):614-20. DOI: 10.1161/01.ATV.0000255581.38523.7c. View

12.

Albertsen P, Klotz L, Tombal B, Grady J, Olesen T, Nilsson J . Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2013; 65(3):565-73. DOI: 10.1016/j.eururo.2013.10.032. View

13.

Caidahl K, Hartford M, Ravn-Fischer A, Lorentzen E, Yndestad A, Karlsson T . Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2019; 74(6):774-782. DOI: 10.1016/j.jacc.2019.06.030. View

14.

Kan W, Hsieh K, Chen Y, Ho C, Hong C, Chiang C . Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients with Prostate Cancer. J Urol. 2021; 207(4):841-850. DOI: 10.1097/JU.0000000000002340. View

15.

Kaufman J, Vermeulen A . The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005; 26(6):833-76. DOI: 10.1210/er.2004-0013. View

16.

Devereaux P, Duceppe E, Guyatt G, Tandon V, Rodseth R, Biccard B . Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018; 391(10137):2325-2334. DOI: 10.1016/S0140-6736(18)30832-8. View

17.

Cirne F, Aghel N, Petropoulos J, Klotz L, Lenihan D, Saad F . The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. Eur Heart J Cardiovasc Pharmacother. 2021; 8(3):253-262. DOI: 10.1093/ehjcvp/pvab005. View

18.

Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A . Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011; 165(5):687-701. DOI: 10.1530/EJE-11-0447. View

19.

Shore N, Saad F, Cookson M, George D, Saltzstein D, Tutrone R . Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020; 382(23):2187-2196. DOI: 10.1056/NEJMoa2004325. View

20.

Thomsen F, Sandin F, Garmo H, Franck Lissbrant I, Ahlgren G, Van Hemelrijck M . Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. Eur Urol. 2017; 72(6):920-928. DOI: 10.1016/j.eururo.2017.06.036. View